VEDERA试验:极早期类风湿关节炎中依那西普联合甲氨蝶呤与甲氨蝶呤延迟联合依那西普的实用性随机对照试验
该实用性开放标签随机对照试验纳入120例病程≤12个月的极早期类风湿关节炎患者,比较一线依那西普联合甲氨蝶呤(ETN+MTX)与达标治疗甲氨蝶呤(MTX-TT,24周未达标加用ETN)的策略。48周DAS28-ESR缓解率分别为52%与38%(OR 1.6,95%CI 0.8-3.5,p=0.211),未证实先前报道的更大优势;持续缓解率ETN+MTX组42%优于MTX-TT组27%(p=0.035)。
要点
- 极早期RA中一线ETN+MTX较MTX-TT未显示显著更高的48周缓解率(52% vs 38%,p=0.211)。
- ETN+MTX组持续DAS28-ESR缓解率显著高于MTX-TT组(42% vs 27%,p=0.035)。
- 两种策略均未使多数患者达到缓解,但超声证实各臂超过90%患者PD完全抑制。
核心结论
- 在极早期RA中未证实一线ETN+MTX较MTX-TT具有先前报道的更大疗效优势。
- 两种策略均未使多数患者达到缓解,尽管超声证实局部炎症抑制。
- 探索性分析提示MTX-TT失败后使用ETN的缓解率可能低于一线使用ETN。
研究设计与样本
- 实用性、开放标签、随机对照试验,纳入未治疗、病程≤12个月、DAS28-ESR≥3.2且RF/ACPA阳性或超声PD阳性的极早期RA患者。
- 随机1:1分组至ETN+MTX或MTX-TT(24周DAS28-ESR≥2.6时升级加用ETN,并按方案时间点给予肌注糖皮质激素)。
- 共随机120例,每组60例;主要终点为48周DAS28-ESR缓解。
主要发现
- 48周DAS28-ESR缓解率ETN+MTX组52%、MTX-TT组38%(OR 1.6,95%CI 0.8-3.5,p=0.211)。
- 24周缓解率ETN+MTX组38%、MTX-TT组33%。
- 持续DAS28-ESR缓解率ETN+MTX组42%、MTX-TT组27%(p=0.035)。
- 48周时两组PD完全抑制均超过90%。
- 探索性分析:一线ETN治疗24周后达到缓解的OR为2.84(95%CI 0.8-9.6),对比MTX后使用ETN。
关键数值与推荐
- 纳入标准:症状≤12个月、DAS28-ESR≥3.2、RF和/或ACPA阳性,或RF/ACPA阴性时超声PD阳性。
- MTX-TT组在24周DAS28-ESR≥2.6时升级加用ETN。
- 主要终点为48周DAS28-ESR缓解。
临床怎么用
- 极早期RA中一线生物制剂联合策略未显示显著优于达标治疗策略的缓解率。
- MTX-TT失败后延迟使用ETN的缓解率可能低于一线使用ETN,支持早期有效控制炎症。
- 超声PD抑制提示两种策略均可有效抑制局部炎症,但临床缓解率仍有限。
局限性
- 开放标签设计可能影响结果解读。
- 样本量120例,探索性分析置信区间宽。
- 主要终点未达统计学显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We sought to confirm in very early rheumatoid arthritis (ERA) a much greater superiority (30%) of first-line etanercept+methotrexate (ETN+MTX) over treat-to-target MTX (MTX-TT) than previously reported in ERA (14%); and explore whether ETN following initial MTX secures a comparable response to first-line ETN+MTX. METHODS: Pragmatic, open-label, randomised controlled trial of treatment-naïve ERA (≤12 months symptom), Disease Activity Score 28 joint (DAS28)-erythrocyte sedimentation rate (ESR) ≥3.2, rheumatoid factor (RF)+/-anticitrullinated peptide antibody (ACPA) positive or ultrasound power Doppler (PD) if RF and ACPA negative. Subjects were randomised 1:1 to ETN+MTX; or MTX-TT, escalated to ETN if week 24 DAS28-ESR ≥2.6 and intramuscular corticosteroid at protocolised time points. Primary endpoint of week 48 DAS28ESR remission with clinical and imaging secondary endpoints. RESULTS: We randomised 120 patients, 60 to each arm (71% female, 73% RF/84% ACPA positive, median (IQR) symptom duration 20.3 (13.1, 30.8) weeks; mean (SD) DAS28 5.1 (1.1)). Remission rates with ETN+MTX and MTX-TT, respectively, were 38% vs 33% at week 24; 52% vs 38% at week 48 (ORs 1.6, 95% CI 0.8 to 3.5, p=0.211). Greater, sustained DAS28-ESR remission observed with ETN+MTX versus MTX-TT (42% and 27%, respectively; p=0.035). PD was fully suppressed by week 48 in over 90% in each arm. Planned exploratory analysis revealed OR 2.84, 95% CI 0.8 to 9.6) of achieving remission after 24 weeks of ETN administered first line compared with administered post-MTX. CONCLUSIONS: Compared with remission rates typically reported with first-line tumour necrosis factor inhabitor+MTX versus MTX-TT, we did not demonstrate a larger effect in very ERA. Neither strategy conferred remission in the majority of patients although ultrasound confirmed local inflammation suppression. Poorer ETN response following failure of MTX-TT is also suggested. Trial registration number NCT02433184.
引用
- Emery P, Horton S, Dumitru RB, et al. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. Ann Rheum Dis. 2020. PMID: 31996367. doi:10.1136/annrheumdis-2019-216539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。